Advertisement

Advertisement

CTOR Stock Latest News

Citius Oncology Secures New Financing to Support LYMPHIR

Company AnnouncementsCitius Oncology Secures New Financing to Support LYMPHIR

Citius Oncology Begins First European Expansion of LYMPHIR

PremiumCompany Announcements

Citius Oncology Begins First European Expansion of LYMPHIR

9d ago

Citius Oncology announces initial shipment of LYMPHIR to Europe

PremiumThe Fly

Citius Oncology announces initial shipment of LYMPHIR to Europe

10d ago

Citius Oncology Faces Nasdaq Non-Compliance, Delisting Risk Looms

PremiumCompany Announcements

Citius Oncology Faces Nasdaq Non-Compliance, Delisting Risk Looms

10d ago

Citius Oncology highlights early LYMPHIR commercial traction, expansion

PremiumCompany Announcements

Citius Oncology highlights early LYMPHIR commercial traction, expansion

1M ago

Citius Oncology provides commercial update on lymphir launch

PremiumThe FlyCitius Oncology provides commercial update on lymphir launch

1M ago

Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data

Company Announcements

Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data

2M ago

Citius Oncology’s Lymphir shows positive results in gynecologic cancers

The Fly

Citius Oncology’s Lymphir shows positive results in gynecologic cancers

2M ago

Citius Oncology Announces Positive Phase 1 LYMPHIR Data

PremiumCompany Announcements

Citius Oncology Announces Positive Phase 1 LYMPHIR Data

2M ago

Citius Oncology reports results from Phase 1 trial evaluating LYMPHIR

PremiumThe Fly

Citius Oncology reports results from Phase 1 trial evaluating LYMPHIR

2M ago

Citius Oncology reports Q1 EPS (6c) vs. (9c) last year

PremiumThe Fly

Citius Oncology reports Q1 EPS (6c) vs. (9c) last year

3M ago

Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir

PremiumThe Fly

Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir

3M ago

Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year

PremiumThe FlyCitius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year

3M ago

CTOR Earnings this Week: How Will it Perform?

Pre-Earnings

CTOR Earnings this Week: How Will it Perform?

3M ago

Citius files to sell shares of common stock underlying warrants for holders

The Fly

Citius files to sell shares of common stock underlying warrants for holders

4M ago

Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption

PremiumCompany Announcements

Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption

4M ago

Citius Oncology reports FY25 EPS (34c) vs. (31c) last year

PremiumThe Fly

Citius Oncology reports FY25 EPS (34c) vs. (31c) last year

5M ago

Citius Oncology Raises $18M Through Direct Offering

PremiumCompany Announcements

Citius Oncology Raises $18M Through Direct Offering

5M ago

Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering

PremiumThe Fly

Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering

5M ago

Citius Oncology expands Lymphir distribution to Turkey and Middle East

PremiumThe FlyCitius Oncology expands Lymphir distribution to Turkey and Middle East

5M ago

Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma

Company Announcements

Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma

5M ago

Citius Oncology announces U.S. commercial launch of LYMPHIR

The Fly

Citius Oncology announces U.S. commercial launch of LYMPHIR

5M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >